Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,911 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Leukemia Acute Lymphoid Leukemia (ALL) Clear all
Active, not recruiting Phase 3 Interventional

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

NCT04530565
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
207
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 8, 2026, 2:06 AM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

NCT03844048
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Harvey, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 8, 2026, 2:06 AM EDT
Not yet recruiting Phase 1 Interventional

Study Of KITE-753 in R/R B-Cell ALL

NCT07674823
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
KITE-753
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 8, 2026, 2:06 AM EDT
Not listed No phase listed Observational

Point-of-Care Ultrasound for Pediatric Thoracic Trauma: A Multi-Institutional Trial

NCT05025150
View directory record Official record
Conditions
Trauma Chest, Pediatric ALL
Interventions
Not listed
Lead sponsor
Sutter Health
Other
Eligibility
0 Years to 21 Years
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 8, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Results available

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

NCT01614197
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Interventions
Temsirolimus, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 8, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

NCT05800210
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Interventions
Miltenyi CliniMACS Prodigy ® system
Device
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 8, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

NCT00253513
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 8, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

NCT00005950
View directory record Official record
Conditions
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
nelarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 8, 2026, 2:06 AM EDT
Terminated Phase 1Phase 2 Interventional

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

NCT03808610
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Rituximab, Venetoclax, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 8, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies

NCT00145613
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Secondary AML, Myelodysplastic Syndrome (MDS), Secondary MDS, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Paroxysmal Nocturnal Hemoglobinuria (PNH), Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies
Procedure · Device · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2009 · Synced Oct 8, 2026, 2:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04404660
View directory record Official record
Conditions
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Interventions
AUTO1
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 8, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

NCT02639559
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
BL-8040, Leukapheresis, Hematopoietic cell transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 8, 2026, 2:06 AM EDT
Active, not recruiting Phase 1 Interventional

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

NCT02146924
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 8, 2026, 2:06 AM EDT
Completed No phase listed Observational

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

NCT00437060
View directory record Official record
Conditions
Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Cognitive Side Effects of Cancer Therapy, Long-Term Effects Secondary to Cancer Therapy in Children, Neurotoxicity Syndrome, Psychological Impact of Cancer, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
Cognitive Assessment, Diffusion Tensor Imaging, Laboratory Biomarker Analysis, Pharmacological Study, Psychosocial Assessment and Care
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Downey, California • Long Beach, California + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 8, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

NCT00911066
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
MLN4924, Azacitidine
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 8, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929
View directory record Official record
Conditions
Cancer
Interventions
anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 8, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

NCT03613727
View directory record Official record
Conditions
Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
Interventions
Intravenous (IV) and oral Vitamin C
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 77 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 8, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

NCT06128070
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate, Multigated Acquisition Scan, Ruxolitinib Phosphate, Tacrolimus
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 8, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00027560
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 8, 2026, 2:06 AM EDT
Completed No phase listed Observational

Eligibility Screening for a NCI Pediatric Oncology Branch Research Study

NCT00026780
View directory record Official record
Conditions
Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia, Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 35 Years
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 8, 2026, 2:06 AM EDT
Completed No phase listed Observational Results available

Pediatric Cardiac Output Monitoring Observational Study

NCT04465370
View directory record Official record
Conditions
Pediatric ALL
Interventions
Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
12 Years to 18 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 8, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

NCT00529360
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 8, 2026, 2:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

NCT04726241
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions
Biospecimen Collection
Procedure
Lead sponsor
PedAL BCU, LLC
Other
Eligibility
Up to 22 Years
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
164
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 8, 2026, 2:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

NCT03386513
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Interventions
IMGN632
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 8, 2026, 2:06 AM EDT